We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Creo Medical Group Plc | CREO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -0.71% | 35.00 | 16:08:56 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 35.25 | 34.75 | 35.25 | 35.00 | 35.25 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 01/5/2024 06:11 by porky9 @Master InvestorAnd you know that because..... Going out on a limb here, as current 35p share price level holding well but i recon i will still be able to get my 15p buy in target later this year before any uplift comes, they wont get BE without more cash is my call. Lets see if i'm proven wrong. From my experience investing in other healthcare stocks where they intend to win major NHS and private health sector deals, irrespective of the possible financial advantages from saved time, it will take significantly longer to win these contracts simply because there is a massive upfront cost and training time and cost to change. Not to mention the gestation period to get a deal from creation of tender process to a decision to actually go with it - snail pace progress for these sorts of decisions is understatement of the year. The albatross around CREOs neck is the cost of sales. The current cash burn to deliver the sales they have is ridiculous. I know they talk about ultimately bringing cash burn down but we are yet to see material proof of that. Otherwise, bloody good tech that will make a difference, that's why this remains on my watch list but im in no hurry, with a £130m mcap whilst losing over £16m a year on £31m of sales and a dwindling cash reserve its currently more than fully priced imo. But good luck to the bulls here |
Posted at 28/4/2024 17:52 by pacsltd Porky, CREO had a raise just over a year ago. So do you think the directors told porkies (excuse the pun) when they suggested at the time:-"The Company is pursuing the Fundraising in order to raise sufficient funds to maintain momentum in the business building on the success of 2022 and the milestones that it has achieved since IPO. The Fundraising is intended to enable the Company to progress into the next stage of the development and commercialisation of its minimally invasive electrosurgical devices, and the Directors expect that the Fundraising will provide the Company with a pathway to being cash flow break even and, ultimately, to profitability as well as give comfort to existing customers, suppliers and partners of increased balance sheet strength. ... The Group continues to progress towards profitability with revenues continuing to grow and the intensive investment product development and launch phase coming to an end. Material reductions in operating costs have contributed to a reduced underlying EBITDA loss for FY22 compared to FY21, which is expected to be in-line with market expectations. Management considers that this combination of strong core product revenue growth and active cost control means that the business is well-positioned to further reduce cash burn in FY23 and remains on track for EBITDA break even during FY25, also in-line with market expectations." So is Porky suggesting that CREO directors got it wrong or misled the institution and private investors a year ago? Just saying. |
Posted at 24/4/2024 13:23 by hatfullofsky peterrr3 - Gulliford is no scientist he was an early investorCraig has over 25 years’ experience in building international businesses from early stage through to significant scale. In January 1999, Craig joined a start-up software and hardware business where, as COO, he was part of a small team that grew the Company both organically and through acquisition, from a loss-making start-up to a profitable business delivering significant shareholder returns and an exit in 2007. If anything he'll be polishing the company for an exit at some point but the pay themselves very handsomley |
Posted at 29/3/2024 11:47 by dr biotech One investor implies they will be taken out by intuitive |
Posted at 12/3/2024 14:11 by dr biotech But it was at an investor conference though. I've never been to one - seemed like 100 PI's, not sure how many of them would be looking to invest or how much, a chance for PR though. |
Posted at 12/3/2024 12:43 by hatfullofsky Yes I would have expected it to at least have moved to - in development.In this investormeet presentation from 12/09/23 https://www.investor |
Posted at 08/2/2024 19:40 by cyberbub Someone needs to tell the company ASAP then, as it may be putting investors off. They seem to have missed it! |
Posted at 23/1/2024 08:05 by wan Two companies on Creo investor minds -3 bellwether companies to watch as medtech earnings season begins J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports. Published Jan. 22, 2024 RBC Capital Markets analysts were similarly upbeat, writing about “positive momentum exiting 2023 for both procedure volumes and capital spending” in a note to investors last week. A clearer picture of how the medtech industry fared in the fourth quarter and last year, and how companies expect to perform across 2024, will begin to emerge when J&J and Intuitive report results on Tuesday. Meanwhile, Abbott will report on Wednesday morning. Here, we preview what to look out for in the first week of earnings for the industry: Full story - |
Posted at 12/1/2024 07:45 by wan Intuitive is guiding for growth in procedures, robotic placements, and revenues -Intuitive CEO: Strong robot placements offset bariatric surgery slowdown Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries. Published Jan. 11, 2024 the robotic surgery leader is also seeing strong system placements and growth in general surgeries, CEO Gary Guthart told investors at the J.P. Morgan Healthcare Conference in San Francisco. The company preannounced that overall procedures assisted by its da Vinci robot grew 21% in the fourth quarter, above analysts’ expectations. The momentum prompted Intuitive to forecast an increase of about 13% to 16% in da Vinci procedures worldwide in 2024. In 2023, Intuitive’s da Vinci procedure growth was 22%, as almost 2.29 million surgeries were performed with the systems. The company placed 415 da Vinci robots with customers in the fourth quarter alone, up 12% from the same period a year ago. Preliminary fourth-quarter revenue rose 17% to about $1.93 billion. William Blair analyst Brandon Vazquez said the preliminary fourth-quarter results beat expectations in nearly all categories. “The bottom line is that Intuitive is clearly heading into 2024 with strong momentum,” Vazquez said in a report to clients. Full story - Staying with Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company - The following, also from the above Medtechdive link, provides food for thought - At the J.P. Morgan event, Guthart declined to say whether Intuitive plans to roll out a next-generation multi-port robot in the year ahead, a topic of interest among investors. “The fact that management didn’t comment leaves open the possibility for a launch this year,” J.P. Morgan analyst Robbie Marcus said in a research note after the presentation, pointing out that the executives made clear last year a new robot would not come in 2023. |
Posted at 12/10/2023 10:36 by xxxxxy Creo Medical Group PLC Investor PresentationSource: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
